Phenothiazine As Three Cyclos Of Polycyclo Ring System Having At Least Four Cyclos Patents (Class 544/31)
  • Patent number: 9028728
    Abstract: The present invention relates to photochromic materials that include one or more indeno-fused naphthopyrans that have particular groups at the 7, 11, and 13 positions thereof, and at the position alpha to the oxygen of the pyran ring thereof. With some embodiments, hydrogen or an alkoxy group is bonded to the 7 position, an optionally substituted phenyl is bonded to the 11 position, two alkyl groups are bonded to the 13 position, and two optionally substituted phenyl groups are bonded to the position alpha to the oxygen of the pyran ring of the indeno-fused naphthopyran compound. The 13 position of the indeno-fused naphthopyrans is free of ether groups in which an ether oxygen is bonded to the 13 position, and hydroxyl. The present invention also relates to photochromic articles and compositions that include such indeno-fused naphthopyrans.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: May 12, 2015
    Assignee: Transitions Optical, Inc.
    Inventors: Kevin E. Bancroft, Anu Chopra, Xiao-Man Dai, Beon-Kyu Kim, David B. Knowles, Jason R. Lewis, Victor A. Montes, Stephen D. Straight, Massimiliano Tomasulo, Barry Van Gemert, Robert W. Walters, Wenjing Xiao, Huayun Yu, Elizabeth A. Zezinka
  • Patent number: 8481785
    Abstract: The invention pertains to new materials based on sterically inhibited donor arylboranes for the improvement of electron injection and electron transport in organic electronic components like organic light-emitting diodes (OLED's), organic field effect transistors (OFET's), and on organic photovoltaics based components, in particular, organic solar cells.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: July 9, 2013
    Assignee: Osram Opto Semiconductors GmbH
    Inventor: Andreas Kanitz
  • Patent number: 8445483
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: May 21, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, John S. Gunn, Larry S. Schlesinger
  • Patent number: 8388872
    Abstract: The present invention provides a photochromic material which is an indeno-fused naphthopyran of structural formulas I or II, having a pi-conjugation extending group bonded to the 11-position of the indeno-fused naphthopyran, the pi-conjugation extending group having at least one pendent halo-substituted group bonded thereto. The pi-conjugation extending group extends the pi-conjugation system of said indeno-fused naphthopyran. The 13-position of the indeno-fused naphthopyran is substantially free of spiro-substituents. The invention further provides photochromic materials of specified structure, photochromic compositions, photochromic articles and optical elements that include the photochromic material.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: March 5, 2013
    Assignee: Transitions Optical, Inc.
    Inventors: Anu Chopra, Jun Deng, Beon-Kyu Kim, David B. Knowles, Frank F. Molock, Jr., Victor A. Montes, Stephen D. Straight, Wenjing Xiao, Huayun Yu
  • Publication number: 20130053555
    Abstract: The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), and the corresponding compounds.
    Type: Application
    Filed: March 29, 2011
    Publication date: February 28, 2013
    Inventors: Amir Hossain Parham, Christof Pflumm, Philipp Stoessel, Arne Buesing, Dominik Joosten
  • Publication number: 20130026422
    Abstract: The present invention relates to a compound according to formula (I), to the use thereof in an electronic device and to an electronic device which comprises one or more compounds according to formula (I).
    Type: Application
    Filed: March 16, 2011
    Publication date: January 31, 2013
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm
  • Publication number: 20120328530
    Abstract: A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R2, R3 and R4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R1 is not methyl or hydrogen when each of R3 and R4 is methyl or hydrogen.
    Type: Application
    Filed: March 11, 2011
    Publication date: December 27, 2012
    Applicant: PHARMALUCIA LIMITED
    Inventor: Mark Wainwright
  • Patent number: 8308996
    Abstract: A photochromic chromene compound which develops a color of a neutral tint, has high color optical density, a high fading speed and high durability, and has an indeno(2,1-f)naphtho(1,2-b)pyran structure represented by the following formula as the basic skeleton, wherein a sulfur-containing substituent selected from thiol group, alkylthio group, alkoxyalkylthio group, haloalkylthio group, cycloalkylthio group, arylthio group and heteroarylthio group is bonded to the 6-position and/or 7-position carbon atom(s).
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: November 13, 2012
    Assignee: Tokuyama Corporation
    Inventors: Toshiaki Takahashi, Junji Takenaka, Junji Momoda, Kazuhiro Teranishi
  • Patent number: 8308995
    Abstract: A chromene compound represented by the following formula (1): wherein R1, R2, R3, R4, R5, R6, m, and n are defined in the specification. The chromene compound is rarely deteriorated by exposure.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: November 13, 2012
    Assignee: Tokuyama Corporation
    Inventors: Soko Kasai, Shinobu Izumi
  • Publication number: 20120227802
    Abstract: The present invention provides a organic compound of the general structural formula 1 and photovoltaic device and photovoltaic layer comprising thereof Said organic compound forms rod-like supramolecules and absorbs electromagnetic radiation in at least one predetermined spectral subrange within a wavelength range from 400 to 3000 nm with excitation of electron-hole pairs. The polycyclic core Cor1, the bridging group B, and the polycyclic core Cor2 form a molecular system selected from the list comprising donor-bridge-acceptor-bridge-donor and acceptor-bridge-donor-bridge-acceptor in which a dissociation of excited electron-hole pairs is carried out. A solution of the organic compound or its salt forms a solid photovoltaic layer on a substrate.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicant: Cryscade Solar Limited
    Inventors: Pavel KHOKHLOV, Pavel Ivan Lazarev, Alexey Nokel
  • Patent number: 8263589
    Abstract: The invention relates generally to the use of diaminophenothiazine compounds to inhibit or reverse the aggregation of synuclein, and for their use in the manufacture of medicaments for this purpose (e.g. for the treatment of Parkinson's Disease). Also provided are related methods of detecting or labelling of aggregated synuclein.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: September 11, 2012
    Assignee: Wista Laboratories Ltd.
    Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley
  • Patent number: 8207146
    Abstract: The present invention relates to substituted phenothiazines with a double bond and physiologically acceptable salts thereof, and their use as a medicament.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: June 26, 2012
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Elisabeth Defossa, Dieter Schmoll, Axel Dietrich, Johanna Kuhlmann-Gottke, Karl-Christian Engel
  • Patent number: 8158784
    Abstract: The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: April 17, 2012
    Assignee: Pierre Fabre Medicament
    Inventors: Charles Mioskowski, Vanessa Gonnot, Rachid Baati, Marc Nicolas
  • Patent number: 8158037
    Abstract: The present invention provides ophthalmic devices comprising at least one photochromic material which is an indeno-fused naphthopyran having a pi-conjugation extending group bonded to the 11-position of the indeno-fused naphthopyran, the pi-conjugation extending group having at least one pendent halo-substituted group bonded thereto. The pi-conjugation extending group extends the pi-conjugation system of said indeno-fused naphthopyran. The 13-position of the indeno-fused naphthopyran is substantially free of spiro-substituents. The invention further provides photochromic materials of specified structure, photochromic compositions, photochromic articles and optical elements that include the photochromic materials. Other non-limiting embodiments relate to methods of making the ophthalmic devices comprising photochromic materials.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 17, 2012
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Anu Chopra, Jun Deng, Beon-Kyu Kim, David B. Knowles, Frank F. Molock, Jr., Victor A. Montes, Stephen D. Straight, Wenjing Xiao, Huayun Yu
  • Patent number: 8147725
    Abstract: The present invention provides a photochromic material which is an indeno-fused naphthopyran having a pi-conjugation extending group bonded to the 11-position of the indeno-fused naphthopyran, the pi-conjugation extending group having at least one pendent halo-substituted group bonded thereto. The pi-conjugation extending group extends the pi-conjugation system of said indeno-fused naphthopyran. The 13-position of the indeno-fused naphthopyran is substantially free of spiro-substituents. The invention further provides photochromic materials of specified structure, photochromic compositions, photochromic articles and optical elements that include the photochromic material.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 3, 2012
    Assignee: Transitions Optical, Inc
    Inventors: Anu Chopra, Jun Deng, Beon-Kyu Kim, David B. Knowles, Frank Molock, Victor A. Montes, Stephen D. Straight, Wenjing Xiao, Huayun Yu
  • Patent number: 8147726
    Abstract: A chromene compound represented by the following formula (1): wherein R1, R2, R3, R4, R5, R6, m, and n are defined in the specification. The chromene compound is rarely deteriorated by exposure.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: April 3, 2012
    Assignee: Tokuyama Corporation
    Inventors: Soko Kasai, Shinobu Izumi
  • Publication number: 20120058995
    Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the e//i method comprises the steps of in order: a thiosulfonic acid formation (TSAF) as illustrated below, wherein the reaction is carried out in the presence of a thio sulfate and an oxidizing agent that is or comprises persulfate an oxidative coupling (OC); and a ring closure (RC). The resulting compounds and compositions comprising them (e.g., tablets, capsules) are useful in methods of medical treatment and diagnosis, etc., for example, tauopathies, or Alzheimer's disease (AD).
    Type: Application
    Filed: May 11, 2010
    Publication date: March 8, 2012
    Applicant: WisTa Laboratories Ltd.
    Inventors: Christopher Paul Larch, John Mervyn David Storey, Craig Williamson, Colin Marshall, Steven John Kemp
  • Publication number: 20100063034
    Abstract: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.
    Type: Application
    Filed: September 1, 2009
    Publication date: March 11, 2010
    Inventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
  • Publication number: 20090069308
    Abstract: The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses.
    Type: Application
    Filed: March 9, 2007
    Publication date: March 12, 2009
    Applicant: Pierre Fabre Medicament
    Inventors: Jean Deregnaucourt, Etienne Andre, Jacky Tisne-Versailles
  • Publication number: 20080303003
    Abstract: The present invention relates to anthracene derivatives, to the use thereof in organic electroluminescent devices, and to organic electroluminescent devices comprising these compounds.
    Type: Application
    Filed: November 17, 2006
    Publication date: December 11, 2008
    Applicant: MERCK PATENT GMBH
    Inventors: Holger Heil, Philipp Stoessel, Amir Parham, Horst Vestweber
  • Patent number: 7235550
    Abstract: The invention relates to compounds of formula (I): wherein: G1 represents an alkylene chain as defined in the description, A represents R2 and R3 represent hydrogen, alkyl, alkoxy or hydroxy or together form oxo, R4 and R5 represent hydrogen, R1 is as defined in the description, and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: June 26, 2007
    Assignee: Les Laboratoires Servier
    Inventors: Gérald Guillaumet, Marie-Claude Viaud, Hervé Van de Poel, Philippe Delagrange, Caroline Bennejean, Pierre Renard
  • Patent number: 7141566
    Abstract: The invention relates to compounds of formula (I), the tautomeric and isomeric forms and salts thereof, in addition to a method for production and use thereof in medicaments.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: November 28, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Peter Hölscher, Hartmut Rehwinkel, Stefan Jaroch, Detlev Sülzle, Margrit Hillmann, Gerardine Anne Burton, Fiona Mcdougall McDonald
  • Patent number: 7074782
    Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 and R5 are taken together with the intervening nitrogen to form heterocyclic ring and R is as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: July 11, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Ronald Knegtel, Michael Mortimore, David Kay, Julian M. C. Golec
  • Publication number: 20040254372
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: February 9, 2004
    Publication date: December 16, 2004
    Inventors: Weizheng Xu, Dana V. Ferraris, Jia-He Li, Vincent J. Kalish
  • Patent number: 6821971
    Abstract: The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R comprises ethers or amines; R1 is: a) substituted or unsubstituted aryl; or b) substituted or unsubstituted heteroaryl; R2a and R2b units are each independently hydrogen, ethers, amines, amides, carboxylates, or said units can form a double bond, a carbonyl, or R2a and R2b can be taken together to form a substituted or unsubstituted ring comprising from 4 to 8 atoms, said ring selected from the group consisting of: i) carbocyclic; ii) heterocyclic; iii) aryl; iv) heteroaryl; v) bicyclic; and vi) heterobicyclic.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: November 23, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Michael Philip Clark, Matthew John Laufersweiler, Jane Far-Jine Djung, Biswanath De
  • Publication number: 20030105086
    Abstract: The invention features compounds that act as antimicrobial agents and/or antimicrobial enhancer agents, compositions that include the antimicrobial enhancer agents of the invention, and methods for treating microbial infections using those compositions.
    Type: Application
    Filed: September 6, 2002
    Publication date: June 5, 2003
    Inventors: Arthur F. Michaelis, Hawkins V. Maulding
  • Patent number: 6514984
    Abstract: A method is disclosed for the prevention and treatment of Alzheimer's disease by administering to a human in need thereof an effective amount of a substituted tricyclic sPLA2 inhibitor.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: February 4, 2003
    Assignee: Eli Lilly and Company
    Inventor: August Masaru Watanabe
  • Patent number: 6476021
    Abstract: Novel fused tetracyclic heterocyclic compounds having a potent and highly selective effect of inhibiting cyclic GMP phosphodiesterase (cGMP-PDE) and a high safety; a process for producing the same; drugs characterized by containing at least one of these compounds as the active ingredient, in particular, preventives and/or remedies for pulmonary hypertension, ischemic heart diseases, erectile insufficiency, female sexual dysfunction or diseases against which cGMP-PDE inhibitory effects are efficacious and intermediates useful in producing the above compounds.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: November 5, 2002
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Masayuki Ohashi, Hidemitsu Nishida, Toshiyuki Shudo
  • Patent number: 6468996
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: October 22, 2002
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Patent number: 6426416
    Abstract: The process for chemically modifying metal-free, colored anthraquinone or condensed anthraquinone compounds or the compounds prepared by said process for improving one or more properties thereof such as water dispersibility, compatibility with other organics, or increased chemical reactivity, wherein the process includes providing material with from 1-6 sulfonylhalide groups or sulfonate ester groups or mixtures thereof, and contacting the material under sulfonamido forming conditions with one or more reactants containing one or more poly(oxyalkylene) moieties, each of the reactants having from 1 to 4 functional amino groups, and each of the poly(oxyalkylene) moieties being comprised of from about 4 to about 200 epoxide reactant residues at least about 50 mole percent of which residues contain 2-4 carbons and wherein the total of said epoxide reactant residues is from about 4 to about 600.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: July 30, 2002
    Assignee: Millikan & Companay
    Inventors: Max Allen Weaver, Edward William Kluger, David Jesse Moody
  • Patent number: 6423707
    Abstract: Novel nitroimidazole compounds are provided that have a substituent linked via an ester linkage. The ester linkage may be obtained by derivation of the hydroxyl group of metronidazole. These nitroimidazole ester analogs have anti-microbial activity, with a number of novel compounds having an anti-microbial activity that is significantly improved with respect to metronidazole.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: July 23, 2002
    Assignee: California Pacific Medical Center
    Inventors: Li-Xi Yang, Hui-Juan Wang, Xiandao Pan
  • Publication number: 20020077320
    Abstract: Novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them.
    Type: Application
    Filed: December 6, 2001
    Publication date: June 20, 2002
    Applicant: DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC.
    Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Ashok Channaveerappa Bajji, Shivaramayya Kalchar, Rajagopalan Ramanujam, Ranjan Chakrabarti
  • Patent number: 6407231
    Abstract: This invention relates to a novel, technically advantageous process for the preparation of a mixture of alkylated phenothiazines and diphenylamines. Starting from diphenylamine, this is reacted with elemental sulfur in the presence of iodine, and the substance mixture of diphenylamine and phenothiazine is treated with an olefin in the presence of an acid catalyst.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: June 18, 2002
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Samuel Evans, Stephan Allenbach, Paul Dubs
  • Patent number: 6166202
    Abstract: Benzophenoxazine compounds have formula (I) where X is O or NH, Y is NR.sup.1 R.sup.2 or H, R.sup.1 and R.sup.2 are alkyl or -L-A, L is a linker and A may be a reactive group by means of which the compound is linked to a biomolecule. The compounds can be used as fluorescent dyes for labelling biomolecules.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: December 26, 2000
    Assignee: Amersham Pharmacia Biotech UK Limited
    Inventors: Adrian Simmonds, James N Miller, Christopher John Moody, Elizabeth Swann, Mark Samuel Jonathan Briggs, Ian Edward Bruce
  • Patent number: 5721254
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: October 18, 1995
    Date of Patent: February 24, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5693649
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: October 18, 1995
    Date of Patent: December 2, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5688788
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 18, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5684031
    Abstract: A compound having the structure: ##STR1## wherein (a) n is from 1 to about 3;(b) X is selected from the group consisting of O, S, SO, or SO.sub.2 ; (c) Y is independently hydrogen or straight, branched or cyclic alkyl having from 1 to about 4 carbon atoms, or the Y's are bonded together to form an alkanyl ring having from about 3 to about 7 atoms;(d) Z is hydrogen or straight, branched or cyclic alkyl having from 3 to about 10 atoms other than hydrogen;(e) R.sub.1 is hydrogen or straight, branched or cyclic alkyl, aryl or C(.dbd.NH)--NHR.sub.4 ; and(f) R.sub.2, R.sub.3, and R.sub.4, are independently hydrogen, straight, branched or cyclic alkyl having from one to 10 carbon atoms, or aryl; R.sub.2 and R.sub.3 can be bonded together to form a ring having 5 or 6 atoms.pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.
    Type: Grant
    Filed: February 1, 1996
    Date of Patent: November 4, 1997
    Assignee: The Procter & Gamble Company
    Inventors: John Michael Janusz, James Madison Ridgeway, II
  • Patent number: 5668129
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: September 16, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5574161
    Abstract: The invention relates to novel derivatives of quinolone-carboxylic acid and naphthyridonecarboxylic acid which are substituted in the 7 position by a 1- (or 5-)amino-methyl-2- (or 3-)oxa-7-aza-bicyclo[3.3.0]oct-7-yl residue, their salts, processes for their preparation and antibacterial agents containing these compounds.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: November 12, 1996
    Assignee: Bayer Aktiengesellschaft
    Inventors: Uwe Petersen, Thomas Schenke, Klaus Grohe, Klaus-Dieter Bremm, Rainer Endermann, Karl G. Metzger
  • Patent number: 5520848
    Abstract: A mixture containing phenothiazines which is obtainable by reacting a mixture of diphenylamines comprising______________________________________ 1 to 5% by weight a) diphenylamine of 8 to 18% by b) 4-tert-butyldiphenylamine weight of 21 to 31% by c) one or more compounds selected from weight of i) 4-tert-octyldiphenylamine ii) 4,4'-di-tert-butyldiphenylamine iii) 2,4,4'-tris-tert-butyldiphenylamine 20 to 31% by d) one or more compounds selected from weight of i) 4-tert-butyl-4'-tert-octyldiphenylamine ii) 2,2'- or 2,4'-di-tert-octyldiphenylamine iii) 2,4-di-tert-butyl-4'-tert-octyldiphenylamine, and 15 to 29% by e) the compound weight of i) 4,4'-di-tert-octyldiphenylamine, or the compounds i) 4,4'-di-tert-octyldiphenylamine and ii) 2,4-di-tert-octyl-4'-tert-butyldiphenylamine, ______________________________________with 1 to 200 mol % of elemental sulfur, in the presence of 0.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: May 28, 1996
    Assignee: Ciba-Geigy Corporation
    Inventor: Samuel Evans
  • Patent number: 5496942
    Abstract: A process is provided for preparing a tetrahydrobenzimidazole derivative represented by Formula (Ib): ##STR1## wherein Het representa s heterocyclic group which may be substituted with 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl-lower alkyl group, an aralkyl group, a lower alkoxycarbonyl group, and a halogen atom; and X.sup.2 represents a single bond connected to the carbon atom of the heterocyclic ring as represented by Het. The process comprises reacting a heterocyclic compound represented by Formula (IIIa):Het--X.sup.2 --H (IIIa)wherein Het and X.sup.2 are as defined above, with a carboxylic acid represented by Formula (II): ##STR2## or a reactive derivative thereof.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: March 5, 1996
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Ohta, Tokuo Koide, Takeshi Suzuki, Akira Matsuhisa, Keiji Miyata, Junya Ohmori, Isao Yanagisawa
  • Patent number: 5489603
    Abstract: An insecticidal composition containing a guanidine derivative of the formula: ##STR1## wherein R.sup.1 is an optionally substituted homocyclic or heterocyclic group, n is 0 or 1, R.sup.2 is a hydrogen atom or an optionally substituted hydrocarbon group, R.sup.3 is a primary, secondary or tertiary amino group, X is an electron attractive group such as nitro or trifluoroacetyl group, provided that when n is 0, R.sup.1 is an optionally substituted heterocyclic group or a salt thereof.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: February 6, 1996
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Hideki Uneme, Koichi Iwanaga, Noriko Higuchi, Isao Minamida, Tetsuo Okauchi
  • Patent number: 5413737
    Abstract: A mixture containing phenothiazines which is obtainable by reacting a mixture of diphenylamines comprising______________________________________ 1 to 5% by weight of a) diphenylamine 8 to 18% by weight of b) 4-tert-butyldiphenylamine 21 to 31% by weight of c) one or more compounds selected from i) 4-tert-octyldiphenylamine ii) 4,4'-di-tert-butyldiphenylamine iii) 2,4,4'-tris-tert-butyldiphenylamine 20 to 31% by weight of d) one or more compounds selected from i) 4-tert-butyl-4'-tert-octyldiphenylamine ii) 2,2'- or 2,4'-di-tert- octyldiphenylamine iii) 2,4-di-tert-butyl-4'-tert- octyldiphenylamine, and 15 to 29% by weight of e) the compound i) 4,4'-di-tert-octyldiphenylamine, or the compounds i) 4,4'-di-tert-octyldiphenylamine and ii) 2,4-di-tert-octyl-4'-tert- butyldiphenylamine, ______________________________________with 1 to 200 mol % of elemental sulfur, in the presence of 0.
    Type: Grant
    Filed: April 22, 1994
    Date of Patent: May 9, 1995
    Assignee: Ciba-Geigy Corporation
    Inventor: Samuel Evans
  • Patent number: 5344927
    Abstract: A tetrahydrobenzimidazole derivative represented by formula (I): ##STR1## wherein Het represents a heterocyclic group which may be substituted with 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl-lower alkyl group, an aralkyl group, a lower alkoxy group, a nitro group, a hydroxyl group, a lower alkoxycarbonyl group, and a halogen atom; and X represents a single bond or --NH-- which is bonded to the carbon atom or nitrogen atom of the heterocyclic ring, or a pharmaceutically acceptable salt thereof.The compound of formula (I) and a salt thereof exhibits antagonism against 5-HT.sub.3 receptor.
    Type: Grant
    Filed: March 30, 1993
    Date of Patent: September 6, 1994
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Ohta, Tokuo Koide, Takeshi Suzuki, Akira Matsuhisa, Keiji Miyata, Junya Ohmori, Isao Yanagisawa
  • Patent number: 5269954
    Abstract: The present invention relates to the preparation of antioxidant additives to lubricants and to their use in lubricating compositions. The additives according to the invention have the formula:ArAr'(H)N--(R--X).sub.a --R'Ywhere--Ar and Ar' are identical or different aromatic radicals, R and R', which are identical or different, denote a C.sub.2 -C.sub.18 linear or branched alkylene radical, X denotes an oxygen or sulphur atom or an --NH group, a is an integer between 0 and 5 and Y is chosen from the group consisting of --NR.sub.1 R.sub.2, where R.sub.1 and R.sub.2, which are identical or different, denote a hydrogen atom or a C.sub.1 -C.sub.12 alkyl, alkenyl, cycloalkyl or arylalkyl radical --N.dbd.CH--Ar.sub.1 where Ar.sub.1 is an aryl radical containing at least one phenolic group --NR.sub.1 --CO--Ar.sub.1 and ##STR1## where R.sub.3 denotes a saturated or unsaturated, linear or branched alkyl radical.
    Type: Grant
    Filed: November 25, 1991
    Date of Patent: December 14, 1993
    Assignee: Elf France
    Inventors: Laurent Germanaud, Patrick Azorin, Patrick Turello
  • Patent number: 5124332
    Abstract: Substituted indoles and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.
    Type: Grant
    Filed: January 28, 1991
    Date of Patent: June 23, 1992
    Assignee: Warner-Lambert Company
    Inventors: Lawrence D. Wise, David J. Wurtrow
  • Patent number: 4990615
    Abstract: Triphendioxazine and triphendithiazine direct dyestuffs of the formula ##STR1## in which the substituents have the meanings given in the description produce on natural and synthetic OH-- and NH-- containing materials clear blue dyeings having good light and wet properties.
    Type: Grant
    Filed: September 12, 1989
    Date of Patent: February 5, 1991
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hermann Henk, Wolfgang Harms, Peter Wild
  • Patent number: 4983493
    Abstract: A dye for heat sensitive transfer recording represented by formula (I): ##STR1## wherein Q.sup.1 represents an atomic group, which includes at least one nitrogen atom, which is required, together with the carbon atoms to which said atomic group is bonded, to form an at least five membered nitrogen containing heterocyclic ring; R.sub.1 represents an acyl group or a sulfonyl group; R.sub.2 represents a hydrogen atom or an aliphatic group which has from 1 to 6 carbon atoms; R.sub.3 represents a hydrogen atom, a halogen atom, an alkoxy group, or an aliphatic group which has from 1 to 6 carbon atoms; R.sub.4 represents a halogen atom, an alkoxy group, or an aliphatic group which has from 1 to 6 carbon atoms; n represents an integer of from 0 to 4; R.sub.3 may be joined to R.sup.1, R.sup.2, or R.sup.4 to form a ring; R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, an aliphatic group which has from 1 to 6 carbon atoms, or an aromatic group; R.sup.5 and R.sup.
    Type: Grant
    Filed: July 14, 1988
    Date of Patent: January 8, 1991
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Takeshi Nakamine, Michio Ono, Seiiti Kubodera
  • Patent number: 4962197
    Abstract: A compound having the formula ##STR1## in which X is O, S, or Se; each R.sub.1, R.sub.2, and R.sub.3, independently, is H, a lower alkyl, or aralkyl; A is a saturated or unsaturated ring; and each Z.sub.1, Z.sub.2, Z.sub.3, Z.sub.4, Z.sub.5, Z.sub.6, Z.sub.7, or Z.sub.8, independently, is H or a halogen,provided that when X is O, at least one group Z is a halogen; when either Z.sub.2 or Z.sub.3 is a halogen, at least one of R.sub.2 or R.sub.3 is H; and when both Z.sub.2 and Z.sub.3 are halogens, both R.sub.2 and R.sub.3 are H;or a pharmaceutically acceptable salt thereof.The compounds are useful for photo-inactivation of cancer cells.
    Type: Grant
    Filed: February 12, 1988
    Date of Patent: October 9, 1990
    Assignee: Rowland Institute for Science
    Inventors: James W. Foley, Louis Cincotta